Brunton Status Report March, 13

8/22/2019 Brunton Status Report March, 13

1/52

printer test sent on: 9th May

Printer date: 8/16/2013

Copy editing : US

Proof reading: US

Section No Section Name Chapter No Chapter Name

Front Matter

1 Drug Invention and the Pharmaceutical Industry

2

Pharmacokinetics: The Dynamics of Drug Absorption,

Distribution, Metabolism, and Elimination

3Pharmacodynamics: Molecular Mechanisms of Drug

Action4 Drug Toxicity and Poisoning

5 Membrane Transporters and Drug Response

6 Drug Metabolism

7 Pharmacogenetics

8Neurotransmission: The Autonomic and Somatic Motor

Nervous S stems

9 Muscarinic Receptor Agonists and Antagonists

10 Anticholinesterase Agents

11Agents Acting at the Neuromuscular Junction and

Autonomic Ganglia

12 Adrenergic Agonists and Antagonists

13 -Hydroxytryptamine (Serotonin) and Dopamine

14

Neurotransmission and the Central Nervous System

15

Drug Therapy of Depression and Anxiety Disorders

16 Pharmacotherapy of Psychosis and Mania

17 Hypnotics and Sedatives

18 Opioids, Analgesia, and Pain Management

19 General Anesthetics and Therapeutic Gases

20 Local Anesthetics

21 Pharmacotherapy of the Epilepsies

22 Treatment of Central Nervous System DegenerativeDisorders

23 Ethanol and Methanol

24 Drug Addiction

25Regulation of Renal Function and Vascular Volume

26 Renin and Angiotensin

27Treatment of Myocardial Ischemia and Hypertension

1 General Principles

2 Neuropharmacology

Sample Approved on : Jan 24, 13/ revised sample approved on Feb 5, 13

Sample sent on: Jan 17, 13/ revised sample sent on Feb 1, 13

printer test approved on : 20th May

Printer : CTPS

CIP: To come from MH

Indexing: US


2/52

28 Pharmacotherapy of Congestive Heart Failure

29 Anti-Arrhythmic Drugs

30Blood Coagulation and Anticoagulant, Fibrinolytic, and

Antiplatelet Drugs

31Drug Therapy for Hypercholesterolemia and

D sli idemia32 Histamine, Bradykinin, and Their Antagonists

33 Lipid-Derived Autacoids: Eicosanoids and Platelet-

Activatin Factor

34 Pharmacotherapy of Inflammation, Fever, Pain, and

Gout

35 Immunosuppressants, Tolerogens, and

Immunostimulants

36 Pulmonary Pharmacology

37 Hematopoietic Agents: Growth Factors, Minerals, and

Vitamins

38 Introduction To Endocrinology: The Hypothalamic-

39 Thyroid and Anti-Thyroid Drugs

40 Estrogens and Progestins

41 Androgens

42 Pharmacology of the Adrenal Cortex43 Endocrine Pancreas and Pharmacotherapy of Diabetes

Mellitus and Hypoglycemia44 Agents Affecting Mineral Ion Homeostasis and Bone

Turnover45 Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and

Gastroesophageal Reflux Disease

46 Treatment of Disorders of Bowel Motility and Water

Flux; Anti-Emetics; Agents Used in Biliary and

Pancreatic Disease47 Pharmacotherapy of Inflammatory Bowel Disease

48 General Principles of Antimicrobial Therapy

49 Chemotherapy of Malaria50 Chemotherapy of Protozoal Infections: Amebiasis,

Giardiasis, Trichomoniasis, Trypanosomiasis,

Leishmaniasis, and Other Protozoal Infections

51 Chemotherapy of Helminth Infections

52 Sulfonamides, Trimethoprim-Sulfamethoxazole,

Quinolones, and Agents for Urinary Tract Infection

53 Penicillins, Cephalosporins, and Other -Lactam

Antibiotics54 Aminoglycosides

55 Protein Synthesis Inhibitors and Miscellaneous

Antibacterial Agents56 Chemotherapy of Tuberculosis, Mycobacterium Avium

Complex Disease, and Leprosy

57 Antifungal Agents

58 Antiviral Agents (Nonretroviral)

59 Antiretroviral Agents and Treatment of HIV Infection

60 General Principles of Cancer Chemotherapy

61 Cytotoxic Agents

Hormones and Hormone

Antagonists5

Chemotherapy of Microbial

Diseases7

Drugs Affecting

Gastrointestinal Function6

Inflammation,

Immunomodulation, and

Hematopoiesis

4

CARDIOVASCULAR FUNCTION3


3/52

62 Targeted Therapies: Tyrosine Kinase Inhibitors,

Monoclonal Antibodies, and Cytokines

63 Natural Products in Cancer Chemotherapy: Hormones

and Related Agents

64 Ocular Pharmacology

65 Dermatological Pharmacology

66 Contraception and Pharmacotherapy of Obstetrical and

G necolo ical Disorders67 Environmental Toxicology: Carcinogens and Heavy

Metals

Appendix

Total

Beckywill be getting Permission Credit Lines. For

Figures 3,4,5, & 7

11

Special Systems Pharmacology9

8C emot erapy o Neopastic

Diseases


4/52

PR Start DatePR Received

on

Page Proofs Due

onSent on

Proof Corrections due to

receive from editor

28-Jun-13 28-Jun-13

23-Feb 25-Feb 3-May-13 3-May-13 24-May-13

18-Jan 21-Jan

3-May-13 3-May-13 24-May-13

25-Feb 26-Feb3-May-13 3-May-13 24-May-13


24-Apr 26-Apr 3-May-13 3-May-13 24-May-13



25-Apr 26-Apr3-May-13 3-May-13 24-May-13

26-Apr 3-May-13 3-May-13 24-May-13


8-Feb 11-Feb3-May-13 3-May-13 24-May-13



16-Feb 17-Feb

3-May-13 3-May-13 24-May-13

23-Feb 25-Feb

3-May-13 3-May-13 24-May-13




3-Mar 4-Mar 3-May-13 3-May-13 24-May-13



24-Apr 26-Apr3-May-13 3-May-13 24-May-13



13-May 14-May 24-May-13 24-May-13 14-Jun-13

23-Feb 25-Feb 24-May-13 24-May-13 14-Jun-13



5/52



25-Feb 28-Feb-13 24-May-13 24-May-13 14-Jun-13

8-May-13 10-May-13 24-May-13 24-May-13 14-Jun-13






13-May 17-May-13 24-May-13 24-May-13 14-Jun-13











1-Jun 3-Jun-13 14-Jun-13 14-Jun-13 5-Jul-13





7-Jun 10-Jun 14-Jun-13 14-Jun-13 5-Jul-13

14-Jun-13 14-Jun-13 5-Jul-13



14-Jun-13 14-Jun-13 5-Jul-13






6/52




7-Jun 14-Jun-13 14-Jun-13 5-Jul-13

10-Jun 14-Jun-13 14-Jun-13 5-Jul-13

7-Jun 14-Jun-13 14-Jun-13 5-Jul-13

14-Jun-13 14-Jun-13 5-Jul-13


7/52

Proof corrections actually

received from editor

Proof corrections actually

received from mcgraw hill

Revised proofs and index

(By TD) proofs to

McGraw-Hill due on

Revised pages

actually sent on

9-Aug-13

21-Jun 9-Aug-13

21-Jun

9-Aug-13

21-Jun9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun

9-Aug-13

21-Jun

9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun9-Aug-13

21-Jun 9-Aug-13

21-Jun9-Aug-13


8/52

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun9-Aug-13

21-Jun9-Aug-13

21-Jun 9-Aug-13

21-Jun 9-Aug-13

21-Jun9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13


9/52

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13

9-Aug-13


10/52

Final Printer Files due

to McGraw-Hill

Final Printer Files to mcgraw-

hill actually sent onRemarks

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13


11/52

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13


12/52

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13

16-Aug-13


13/52

EDITOR PREFERENCE SHEET

EDITOR NAME SCHEDULE SHARED ON COMMENTS

Randa Hilal-Dandan 12/28/2012 Confirmed

Lawrence L. Brunton 12/28/2012 Confirmed

All Copy Edited chapters to be sent to editors for review


14/52

MODE OF DELIVERY SHIPPING ADDRESS EMAIL ADDRESS

E Proofs and hardcopy

12828 Harwick Lane,

San Diego, CA 92130. [email protected]

E Proofs and hardcopy

Laurence Brunton

4489 Hermosa Way

San Diego, CA 92103

PH 619-977-4667 [email protected]

chapters 1 to 57 have been sent
mailto:[email protected]:[email protected]:[email protected]:[email protected]


15/52

McGraw-Hill Production Manager: Richard Ruzycka

Project Development Editor: Christie Naglieri

Proofs Distribution: Editors + McGraw-Hill

Arts Proof Distribution: Yes. To be sent to Editors for Review before placing the Arts in Pages.

Compositor - ThomsonXML: Yes

Printer: CTPS

Printer Date: Aug 16, 2013

Milestone Original Scheduled

dates

Actual Dates

Material to Thomson 23-Dec-12 23-Dec-12

Cast Off /Estimate to McGraw-Hill HE 15-Jan-13 15-Jan-13

Thomson to send Sample Chapter to McGraw-Hill HE 28-Jan-13 17-Jan-13

Thomson to send Printer Test 6-May-13

Copyediting completed 15-Mar-13 5-Mar-13

First Page proofs to Editors/MGH for Batch 1 -Sections 1 to 3 (chapters 1 to 24) 3-May-13 3-May-13

First Page proofs to Editors/MGH for Batch 2 -Sections 4 to 6 (chapters 25 to 47) 24-May-13 24-May-13

First Page proofs to Editors/MGH for Batch 3 -Sections 7 to 9 (chapters 48 to 67+Appendix) 14-Jun-13

Return of First Page Proof corrections from Editors to TD 5-Jul-13

Marked revised proofs and index (By TD) proofs to McGraw-Hill 9-Aug-13

Final Print Files to McGraw-Hill HE 16-Aug-13

Editors will get three weeks to review each batch

Schedule for BRUNTON Project


16/52

Remarks

Sample was resent based on

new measurements on Feb

1st. Was approved on Feb

5th


17/52

CE Schedule

Due Date Actual Date

Sample Chapter 1 and 2 28-Dec 28-DecSample Cahpter 26, 30 and 34 11-Jan 11-Jan

Batch 1 Chapter 3- 24 30-Jan 1-Feb

Batch 2 Chapter 25- 47 15-Feb 15-Feb

Batch 3 Chapter 48- 57 28-Feb 26-Feb

Batch 4 Chapter 58-67 28-Feb 1-Mar

Cast Off 2875

Invoice:

Sr No. Invoice No Processed on Chapters Page count cost

1 213004 15-Jan 1,2,26,30 and 34 243 $729

2 213005 29-Jan 3 to 9 251 $753

3 213008 31-Jan 10 to 17 325 $975

4 213010 1-Feb 18 to 24 322 $966

5 213011 11-Feb 25, 27-29, 31-33 386 $1,158

6 213012 15-Feb 35-47 574 $1,722

7 213016 21-Feb 48-57 408 $1,224

8 213018 1-Mar 58-67 489 $1,467

9 213020 3-Mar Preface and appendix 24 $72

3022 $9,066

Estimated Page count 3000 Estim


18/52

ted Cost $ 9000


19/52

Serial

NumberChapter Title

Chapter

NumberNEW Fig No. Art Sent to Editor on

1Drug Invention and the

Pharmaceutical Industr1 1-1

21-Jan

2Drug Invention and the

Pharmaceutical Industr1 1-2

21-Jan

3

Pharmacokinetics: The

Dynamics of Drug Absorption,

Distribution, Metabolism, and

Elimination

2 2-1

21-Jan

4




Elimination

2 2-2

21-Jan

5




Elimination

2 2-3 A&B

21-Jan

6




Elimination

2 2-4 A&B

21-Jan

7




Elimination

2 2-5

21-Jan

8




Elimination

2 2-6

21-Jan

9Pharmacodynamics: Molecular

Mechanisms of Drug Action3 3-1

21-Jan



21-Jan



21-Jan



21-Jan



21-Jan



21-Jan



21-Jan



21-Jan



21-Jan


20/52



21-Jan



21-Jan



21-Jan



21-Jan



21-Jan

23 Drug Toxicity and Poisoning 4 4-121-Jan

24 Drug Toxicity and Poisoning 4 4-2 21-Jan25 Dru Toxicit and Poisonin 4 4-3 21-Jan26 Drug Toxicity and Poisoning 4 4-4 21-Jan27 Drug Toxicity and Poisoning 4 4-5A&B 21-Jan

28 Drug Toxicity and Poisoning 4 4-6A&B 21-Jan

29Membrane Transporters and

Dru Res onse5 5-1

21-Jan


Dru Res onse5 5-2

21-Jan


Dru Res onse5 5-3

21-Jan


Dru Res onse5 5-4

21-Jan


Dru Res onse5 5-5

21-Jan


Dru Res onse5 5-6

21-Jan

35

Membrane Transporters and

Dru Res onse 5 5-7 21-Jan


Dru Res onse5 5-8

21-Jan


Dru Res onse5 5-9

21-Jan


Dru Res onse5 5-10

21-Jan

39 Drug Metabolism 6 6-1 21-Jan

40 Drug Metabolism 6 6-2 21-Jan41 Drug Metabolism 6 6-3 21-Jan42 Drug Metabolism 6 6-4 21-Jan

43 Drug Metabolism 6 6-5 21-Jan44 Drug Metabolism 6 6-6 21-Jan

45 Drug Metabolism 6 6-7 21-Jan46 Drug Metabolism 6 6-8 21-Jan

47 Pharmacogenetics 7 7-1 21-Jan48 Pharmacogenetics 7 7-2 21-Jan

49 Pharmacogenetics 7 7-3 21-Jan50 Pharmacogenetics 7 7-4 21-Jan51 Pharmacogenetics 7 7-5 21-Jan

52 Pharmacogenetics 7 7-6 21-Jan


21/52

53

Neurotransmission: The

Autonomic and Somatic Motor

Nervous S stems

8 8-121-Jan

54



Nervous S stems

8 8-221-Jan

55



Nervous S stems

8 8-321-Jan

56



Nervous S stems

8 8-421-Jan

57



Nervous S stems

8 8-521-Jan

58



Nervous S stems

8 8-621-Jan

59



Nervous S stems

8 8-721-Jan

60Muscarinic Receptor Agonists

and Anta onists 9 9-1 21-Jan

61 Anticholinesterase Agents 10 10-1 21-Jan

62 Anticholinesterase Agents 10 UN 10-1A&B 21-Jan

68

Agents Acting at the

Neuromuscular Junction and

Autonomic Gan lia

11 11-131-Jan

69



Autonomic Gan lia

11 11-2A&B31-Jan

70



Autonomic Gan lia

11 11-331-Jan

71



Autonomic Gan lia

11 11-431-Jan

72



Autonomic Gan lia

11 11-531-Jan

73Adrenergic Agonists and

Anta onists12 12-1

31-Jan


Anta onists12 12-2

31-Jan


Anta onists12 12-3

31-Jan

76

Adrenergic Agonists and

Anta onists 12 12-4 31-Jan

775-Hydroxytryptamine

Serotonin and Do amine13 13-1

31-Jan



31-Jan



31-Jan



31-Jan


22/52



31-Jan



31-Jan



31-Jan

84Neurotransmission and the

Central Nervous S stem14 14-1

31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan

96Drug Therapy of Depression and

Anxiet Disorders15 15-1

31-Jan

97Pharmacotherapy of Psychosis

and Mania16 16-1

31-Jan

98Pharmacotherapy of Psychosis

and Mania16 16-2A&B

31-Jan

Hypnotics and Sedatives 17

THERE ARE NO

FIGURES IN THIS

CHAPTER.

99Opioids, Analgesia, and Pain

Mana ement18 18-1

31-Jan


Mana ement18 18-2

31-Jan


Mana ement18 18-3

31-Jan


Mana ement18 18-4

31-Jan


Mana ement18 18-5

31-Jan

104General Anesthetics and

Thera eutic Gases19 19-1

31-Jan



31-Jan



31-Jan



31-Jan


23/52



31-Jan



31-Jan

110 Local Anesthetics 20 20-1 31-Jan

111Pharmacotherapy of the

E ile sies21 21-1

31-Jan


E ile sies21 21-2

31-Jan


E ile sies21 21-3

31-Jan


E ile sies21 21-4

31-Jan

115Treatment of Central Nervous

System Degenerative Disorders22 22-1

31-Jan



31-Jan

117 Treatment of Central NervousSystem Degenerative Disorders

22 22-331-Jan



31-Jan



31-Jan



31-Jan

121 Ethanol and Methanol 23 23-1 31-Jan

122 Drug Addiction 24 24-1 31-Jan123 Drug Addiction 24 24-2 31-Jan124 Drug Addiction 24 24-3 31-Jan

125Regulation of Renal Function

and Vascular Volume25 25-1

31-Jan



31-Jan



31-Jan

128 Regulation of Renal Functionand Vascular Volume

25 25-431-Jan



31-Jan



31-Jan



31-Jan


24/52



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan



31-Jan

144 Renin and Angiotensin 26 26-016-Feb

145 Renin and Angiotensin 26 26-02 6-Feb

146 Renin and Angiotensin 26 26-03 6-Feb147 Renin and Angiotensin 26 26-04 6-Feb


149 Renin and Angiotensin 26 26-06 6-Feb


151Treatment of Myocardial

Ischemia and H ertension27 27-01

6-Feb

152Pharmacotherapy of Congestive

Heart Failure28 28-01

6-Feb



6-Feb



6-Feb



6-Feb



6-Feb


25/52



6-Feb



6-Feb



6-Feb

160 Anti-Arrhythmic Drugs 29 29-1 6-Feb161 Anti-Arrhythmic Drugs 29 29-2 6-Feb

162 Anti-Arrhythmic Drugs 29 29-3 6-Feb163 Anti-Arrhythmic Drugs 29 29-4 6-Feb164 Anti-Arrhythmic Drugs 29 29-5A&B 6-Feb165 Anti-Arrhythmic Drugs 29 29-6A&B 6-Feb166 Anti-Arrh thmic Dru s 29 29-7 6-Feb

167 Anti-Arrhythmic Drugs 29 29-8 6-Feb168 Anti-Arrhythmic Drugs 29 29-9A-D 6-Feb

169 Anti-Arrhythmic Drugs 29 29-10A&B 6-Feb170 Anti-Arrhythmic Drugs 29 29-11 6-Feb

171

Blood Coagulation and

Anticoagulant, Fibrinolytic, and

Anti latelet Dru s

30 30-16-Feb

172



Anti latelet Dru s

30 30-26-Feb

173



Anti latelet Dru s

30 30-36-Feb

174



Anti latelet Dru s

30 30-46-Feb

175



Anti latelet Dru s

30 30-5A-C6-Feb

176



Anti latelet Dru s

30 30-66-Feb

177Blood Coagulation and


Anti latelet Dru s

30 30-76-Feb

178

Drug Therapy for

Hypercholesterolemia and

D sli idemia

31 31-16-Feb

179

Drug Therapy for

Hypercholesterolemia and

D sli idemia

31 31-26-Feb

180Histamine, Bradykinin, and Their

Anta onists32 32-1

6-Feb

181

Histamine, Bradykinin, and Their

Anta onists 32 32-2 6-Feb

182Histamine, Bradykinin, and Their

Anta onists32 32-3

6-Feb

183

Lipid-Derived Autacoids:

Eicosanoids and Platelet-

Activatin Factor

33 33-16-Feb

184



Activatin Factor

33 33-26-Feb


26/52

185



Activatin Factor

33 33-36-Feb

186



Activatin Factor

33 33-46-Feb

187



Activatin Factor

33 33-56-Feb

188

Pharmacotherapy of

Inflammation, Fever, Pain, and

Gout

34 34-16-Feb

189

Immunosuppressants,

Tolerogens, and

Immunostimulants

35 35-16-Feb

190

Immunosuppressants,

Tolerogens, and

Immunostimulants

35 35-26-Feb

191 Pulmonar Pharmacolo 36 36-1 6-Feb

192 Pulmonary Pharmacology 36 36-2 6-Feb


194 Pulmonary Pharmacology 36 36-46-Feb


196 Pulmonary Pharmacology 36 36-6 6-Feb197 Pulmonary Pharmacology 36 36-7 6-Feb198 Pulmonary Pharmacology 36 36-8 6-Feb

199 Pulmonary Pharmacology 36 36-9 6-Feb200 Pulmonary Pharmacology 36 36-10 6-Feb


202Hematopoietic Agents: Growth

Factors, Minerals, and Vitamins

37 37-1

6-Feb


Factors, Minerals, and Vitamins37 37-2

6-Feb



6-Feb



6-Feb



6-Feb

207 Hematopoietic Agents: GrowthFactors, Minerals, and Vitamins

37 37-66-Feb



6-Feb



6-Feb



6-Feb


27/52

211Introduction To Endocrinology:

The Hypothalamic-Pituitary Axis38 38-1

6-Feb



6-Feb



6-Feb



6-Feb



6-Feb



6-Feb

217 Thyroid and Anti-Thyroid Drugs 39 39-16-Feb

218 Thyroid and Anti-Thyroid Drugs 39 39-2 6-Feb




222 Estrogens and Progestins 40 40-1 6-Feb

223 Estro ens and Pro estins 40 40-2 6-Feb224 Estrogens and Progestins 40 40-3A&B 6-Feb225 Estrogens and Progestins 40 40-4A-C 6-Feb

226 Androgens 41 41-1 6-Feb

227 Androgens 41 41-2 6-Feb228 Androgens 41 41-3 6-Feb

229 Androgens 41 41-46-Feb

230 Androgens 41 41-5A-C 6-Feb

231Pharmacology of the Adrenal

Cortex42 42-1

6-Feb


Cortex42 42-2

6-Feb


Cortex42 42-3

6-Feb


Cortex42 42-4

6-Feb

235 Pharmacology of the AdrenalCortex

42 42-56-Feb


Cortex42 42-6

6-Feb

237

Endocrine Pancreas and

Pharmacotherapy of Diabetes

Mellitus and Hypoglycemia

43 43-1A&B

6-Feb


28/52

238




43 43-2

6-Feb

239




43 43-3

6-Feb

240Endocrine Pancreas and



43 43-4

6-Feb

241




43 43-5

6-Feb

242




43 43-6

6-Feb

243




43 43-7

6-Feb

244




43 43-8A-C

6-Feb

245




43 43-9

6-Feb

246




43 43-10

6-Feb

247Endocrine Pancreas and



43 43-11

6-Feb

248Agents Affecting Mineral Ion

Homeostasis and Bone Turnover44 44-1

6-Feb



6-Feb



6-Feb

251 Agents Affecting Mineral IonHomeostasis and Bone Turnover

44 44-46-Feb



6-Feb



6-Feb



6-Feb


29/52

255

Pharmacotherapy of Gastric

Acidity, Peptic Ulcers, and

Gastroesophageal Reflux

Disease

45 45-1

6-Feb

256




Disease

45 45-2

6-Feb

257




Disease

45 45-3

6-Feb

258




Disease

46 46-1

6-Feb

259

Treatment of Disorders of Bowel

Motility and Water Flux; Anti-

Emetics; Agents Used in Biliary

and Pancreatic Disease

46 46-2

6-Feb

260





46 46-3

6-Feb

261





46 46-4

6-Feb

262





46 46-5

6-Feb

263Pharmacotherapy of

Inflammatory Bowel Disease47 47-1

6-Feb



6-Feb



6-Feb



6-Feb



6-Feb

268General Principles of

Antimicrobial Thera48 48-1

6-Feb



6-Feb


Antimicrobial Thera48 48-3A&B

6-Feb


30/52


Antimicrobial Thera48 48-4A&B

6-Feb



6-Feb

273 Chemotherapy of Malaria 49 49-1 6-Feb274 Chemotherapy of Malaria 49 49-2 6-Feb

275 Chemotherapy of Malaria 49 49-3 6-Feb

Chemotherapy of Protozoal

Infections: Amebiasis,

Giardiasis, Trichomoniasis,

Trypanosomiasis, Leishmaniasis,

and Other Protozoal Infections

50

THERE ARE NO

FIGURES IN THIS

CHAPTER.

276Chemotherapy of Helminth

Infections51 51-1

18-Feb

277Chemotherapy of Helminth

Infections51 51-2

18-Feb

278

Sulfonamides, Trimethoprim-

Sulfamethoxazole, Quinolones,

and Agents for Urinary Tract

Infections

52 52-1

18-Feb

279




Infections

52 52-2

18-Feb

280




Infections

52 52-3

18-Feb

281Penicillins, Cephalosporins, and

Other -Lactam Antibiotics53 53-1

18-Feb



18-Feb



18-Feb



18-Feb



18-Feb

286 Aminoglycosides 54 54-1 18-Feb

287 Aminoglycosides 54 54-2 18-Feb

288 Aminoglycosides 54 54-318-Feb

289

Protein Synthesis Inhibitors and

Miscellaneous Antibacterial

A ents

55 55-118-Feb

290



A ents

55 55-218-Feb


31/52

291



A ents

55 55-318-Feb

292



A ents

55 55-418-Feb

293

Chemotherapy of Tuberculosis,

Mycobacterium Avium Complex

Disease, and Leprosy

56 56-1

18-Feb

294




56 56-2

18-Feb

295




56 56-3

18-Feb

296




56 56-4

18-Feb

297




56 56-5

18-Feb

298 Antifungal Agents 57 57-1 18-Feb

299 Antifungal Agents 57 57-218-Feb

300 Antifungal Agents 57 57-3 18-Feb

301 Antiviral Agents (Nonretroviral) 58 58-118-Feb









310General Principles of Cancer

Chemothera60 60-1

18-Feb

311General Principles of Cancer

Chemothera60 60-2

18-Feb


32/52

312 Cytotoxic Agents 61 61-1A&B 18-Feb

313 Cytotoxic Agents 61 61-2 18-Feb314 Cytotoxic Agents 61 61-3 18-Feb315 Cytotoxic Agents 61 61-4A&B 18-Feb

316 Cytotoxic Agents 61 61-5 18-Feb317 Cytotoxic Agents 61 61-6 18-Feb

318 C totoxic A ents 61 61-7 18-Feb319 Cytotoxic Agents 61 61-8 18-Feb320 Cytotoxic Agents 61 61-9A&B 18-Feb

312

Targeted Therapies: Tyrosine

Kinase Inhibitors, Monoclonal

Antibodies, and Cytokines

62 62-1

18-Feb

313




62 62-2

18-Feb

314




62 62-3

18-Feb

315

Natural Products in Cancer

Chemotherapy: Hormones and

Related A ents

63 63-118-Feb

316



Related A ents

63 63-218-Feb

317



Related A ents

63 63-318-Feb

318 Ocular Pharmacology 64 64-1 18-Feb319 Ocular Pharmacology 64 64-2 18-Feb

320 Ocular Pharmacology 64 64-3A&B 18-Feb

321 Ocular Pharmacology 64 64-4 18-Feb322 Ocular Pharmacology 64 64-5 18-Feb323 Ocular Pharmacology 64 64-6 18-Feb324 Ocular Pharmacolo 64 64-7 18-Feb

325 Dermatological Pharmacology 65 65-118-Feb




329 Dermatological Pharmacology 65 65-5 18-Feb

330

Contraception and

Pharmacotherapy of Obstetrical

and Gynecological Disorders

66 66-1A-C

18-Feb

331

Contraception and

Pharmacotherapy of Obstetrical

and Gynecological Disorders

66 66-2

18-Feb


33/52

332Environmental Toxicology:

Carcinogens and Heavy Metals67 67-1

18-Feb



18-Feb



18-Feb



18-Feb



18-Feb



18-Feb



18-Feb



18-Feb



18-Feb

341

Appendix I Principles of

Prescription Order Writing and

Patient Com liance

Appendix A1-118-Feb


34/52

CommentsRevised arts sent to

editor on

Comments on revised

art from EditorRemarks

Approved on 25 Jan

Approved on 25 Jan

Approved on 25 Jan

Changes mentioned on

25 Jan 29-Jan Approved on Feb 1

Approved on 25 Jan







Approved on 6 feb

Approved on 6 feb

Approved on 6 feb

Approved on 6 feb

Approved on 6 feb


6 Feb 6-Feb


6 Feb 6-Feb

Approved on 6 feb

Approved on 6 feb


35/52

Approved on 6 feb


6 Feb 6-Feb

Approved on 6 feb

Approved on 6 feb

Approved on 6 feb


6 Feb 6-FebApproved on 6 febApproved on 6 febApproved on 6 febApproved on 6 febApproved on 6 feb

Approved on 20 March



Approved on 20 MarchChanges mentioned on

20 March




Approved on 20 MarchChanges mentioned on

20 March

Approved on 14 MarchApproved on 14 MarchApproved on 14 MarchApproved on 14 MarchApproved on 14 MarchApproved on 14 March

Approved on 14 MarchApproved on 14 March

Approved on 14 MarchApproved on 14 MarchApproved on 14 MarchApproved on 14 MarchApproved on 14 MarchApproved on 14 March


36/52








20 March


Approved on 8 AprilApproved on 8 April

Approved on 8 April

Corrections given on 8-

April


April

Approved on 8 April

Approved on 8 April


April

Approved on 8 April

Approved on 8 AprilCorrections given on 8-

April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April


37/52


April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 AprilCorrections given on 8-

April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April


April

Approved on 8 April


April

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April


April

Approved on 9 April

Approved on 9 April

Approved on 9 April


38/52

Approved on 9 April

Approved on 9 April


coorection on 15-mar

approved on 15-mar

approved on 15-mar


approved on 15-mar

approved on 15-mar

approved on 15-mar


approved on 15-mar

approved on 15-mar

approved on 16-mar

approved on 16-marapproved on 16-marapproved on 16-mar

corrections send on 17

March

approved on 17-March







39/52







corrections send on 17

March







AprilApproved on 8 AprilApproved on 8 AprilApproved on 8 AprilCorrections given on 8-

AprilApproved on 8 AprilCorrections given on 8-

April



Correction on 18-March





40/52




Approved on 19 MarchApproved on 19 MarchApproved on 19 MarchApproved on 19 MarchApproved on 19 MarchApproved on 19 MarchApproved on 19 MarchApproved on 19 MarchApproved on 19 MarchApproved on 19 MarchApproved on 19 March

Approved on 8 April

Approved on 8 April

Approved on 8 April

Approved on 8 April


April


April


April



Corrections on 21-

March



Corrections on 21-

March



41/52


Corrections on 21-

March



April

Corrections on 21-

March

Corrections on 21-

March

Approved on 21 MarchCorrections on 21-

MarchApproved on 21 MarchCorrections on 21-

MarchApproved on 21 MarchApproved on 21 MarchApproved on 21 MarchApproved on 21 MarchApproved on 21 MarchApproved on 21 MarchApproved on 21 March




Corrections on 21-

March

Corrections on 21-

March

Corrections on 21-March

Corrections on 21-

March

Corrections on 21-

March

Corrections on 21-

March


42/52





Corrections on 22-

March


correction on 25 March





Approved on 25 MarchApproved on 25 MarchApproved on 25 MarchApproved on 25 March


Approved on 25 MarchApproved on 25 March

correction on 25 MarchApproved on 25 March









43/52



















44/52


















45/52



Approved on 26 MarchApproved on 26 MarchApproved on 26 March











Approved on 28-March

Approved on 28-MarchCorrections on 28-

March




46/52





Corrections on 28-

March

Corrections on 28-

March



MarchApproved on 28-March











March


47/52

Approved on 1-AprilApproved on 1-AprilApproved on 1-AprilApproved on 1-AprilApproved on 1-AprilApproved on 1-AprilApproved on 1-AprilApproved on 1-AprilApproved on 1-April

Approved on 1-April

Approved on 1-April

Approved on 1-April


Corrections on 29

march


approved on 29-Marchapproved on 29-Marchapproved on 29-March

approved on 29-Marchapproved on 29-Marchapproved on 29-Marchapproved on 29-March









48/52

Approved on 1-April

corrections on 1 April

Approved on 1-April

Approved on 1-April

Approved on 1-April

Approved on 1-April

Approved on 1-April

Approved on 1-April

Approved on 1-April

Approved on 9-April


49/52

Julie

Revised schedule

Chapters 5-9, 20-24 (approx 150 pages): 24 April - 27 April

Chapters 25-47 (approx 440 pages): 7 May - 20 May

Chapters 48-67+appendix (approx 360 pages): 31 May - 10 June

Proof Reader


50/52

Actual Chapters sent Actual Dates Chapters received from PR

Chapter 2 18th Jan 21st Jan

Chapter 10 and 11 8th feb 11th feb

Chapter 12 12th Feb 13th feb

Chapter 13 and 14 16th Feb 17th feb

Chapter 1 and 15 23rd feb 25th Feb

Chapter 16, 17 and 26 23rd feb 25th Feb


Chapter 3 26th feb

Chapter 18 26th feb 27th Feb


Chapter 19 3-Mar 4-Mar

Chapters 61-64 11th June

Chapters 65-67 12th JuneChapters 54,57, Appendix 12th June

12th June


51/52

Batch

No of

Pages

Hardcopy for

Editor

Total No

of Pages Sent To Sent On Sent By

Batch 1 423 Yes 423 Dr. Brunton 6-May-13 Saloni

Batch 1 423 Yes 423 Dr. Dandan 6-May-13 Saloni

Batch2 448 Yes 448 Dr. Dandan 27-May-13 Saloni

Batch2 448 Yes 448 Dr. Brunton 28-May-13 Saloni

Batch 3 Yes Dr. Brunton 17-Jun Saloni

Batch 3 Yes Dr. Dandan 17-Jun Saloni


52/52

Airway Bill No Amount (INR)

3880668934 Rs. 2183.7/-

3880668945 Rs. 1890/-

1428071245

3264868633

Brunton Status Report March, 13

Documents

Transcript of Brunton Status Report March, 13